MyoKardia Культура компании

Dr. Eric J. Topol, M.D., has been the Chief Medical Advisor of AT&T Inc. since February 4, 2014. Dr. Topol has been an Advisor at MyoKardia, Inc. since September 14, 2017. He co-founded Molecular Stethoscope, Inc. in 2015. He is editor-in-chief of Medscape and theheart.org. He served as the Chief Innovation Officer and Vice Chairman of The Gary and Mary West Health Institute. Dr. Topol serves as an Advisor at Divlan Inc. He is a Senior Consulting Physician/Senior Consultant cardiologist practitioner of Scripps Clinic and serves as Chief Academic Officer of Scripps Health, Inc., La Jolla, California. He is a world-renowned geneticist, cardiologist. He serves as Principal Investigator for more than 15 international multi-center research trials, including Gusto I-V, Epic, Epilog, Epistent, Pursuit, Caveat, Target, Replace and many others, with cumulatively more than 200,000 patients enrolled. He serves as Professor of Translational Genomics, Department of Molecular and Experimental Medicine at The Scripps Research Institute and was named The Gary and Mary West Chair of Innovative Medicine. He is also the Founding Dean of Scripps School of Medicine. He is a medical innovator in wireless medicine. He served as the Chief Academic Officer of Cleveland Clinic Foundation. He founded the Cleveland Clinic Lerner College of Medicine. Dr. Topol was Professor of Medicine and Genetics of Cleveland Clinic Lerner College of Medicine. He has wealth of knowledge in translational medicine and the burgeoning area of wireless technology. He served as Adjunct Partner of Essex Woodlands Health Ventures. He served as Scientific Consultant of pharmaceutical development program at FMI Holdings Ltd. (also known as Forbes Medi Tech Inc.) since January 7, 2004. He was the First Physician ever to administer recombinant t-PA and 2 different platelet glycoprotein IIb/IIIa inhibitors to patients. His work in the genomics of heart attack has led to discovery of key genes recognized by the American Heart Association top 10 research advances in 2002 and 2004. As a Leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro). In his productive career as a physician-scientist, he has built an international reputation for his ground-breaking research and expertise. A key researcher in the discovery of dysfunctional gene variants ???MEF2A??? and ???FLAP???, Dr. Topol helped identify them as markedly increasing a person's risk of heart attack. He serves as Chairman of Scientific Advisory Board at Biological Dynamics Inc. He served as Unit Chairman of Quintiles Transnational Corp. He served as the Chairman of Medical and Scientific Advisory Board at FMI Holdings Ltd. from January 7, 2004 to November 2004. He served as the Chairman of Department of Cardiovascular Medicine of The Cleveland Clinic Foundation since 1991 (for 15 years). He served as Vice Chairman of the Department of Molecular Cardiology of The Cleveland Clinic Foundation. He serves as a Director of Scripps Translational Science Institute in La Jolla, California. He has been a Director of DexCom, Inc. since July 2009. He serves as a Member of Advisory Board at Trice Imaging, Inc. and Edico Genome Inc. He serves as Member of Advisory Board at Whole Biome, Inc. He serves as a Member of Scientific Advisory Board at GenapSys, Inc. Dr. Topol has been a Member of Scientific Advisory Board at AltheaDx, Inc., since May 2009. He serves as a Member of the Scientific Advisory Board at Danube Pharmaceuticals, Inc., and Arista Laboratories, Inc. (also known as AlliedPath, Inc.). He serves as a Member of Advisory Council at Qualcomm Life, Inc. He serves as a Member of Medical Advisory Board of Medcases, LLC. He serves as Founding Board Member of Gary and Mary West Wireless Health Institute. He serves as a Member of Hbi-3000 Clinical Advisory Board at H???Y??? Bioscience International, LLC. He has been a Director of California Life Sciences Association since August 2010. He serves as Director of Cypher Genomics, Inc. and Silicon Kinetics, Inc. He serves as Member of Scientific Advisory Board at Gilead Sciences Inc. He serves as Director of Jacobs Center for Thrombosis and Vascular Biology. He serves on the editorial board for over 30 peer review medical publications including Circulation, Circulation Research, JACC, AJC, British and the European Heart Journals. Dr. Topol has been a Co-Director of the Heart Center since 1991. He serves as Member of International Scientific Advisory Board at HUYA Bioscience International, LLC and served as its Member of HBI-3000 Clinical Advisory Board. Dr. Topol served as Director of Volcano Corporation since October 2011 until June 3, 2014. He served as an Independent Director of MyoKardia, Inc. from September 2015 to September 14, 2017. He served as a Director of Sotera Wireless, Inc., (also known as Triage Wireless, Inc.). He served as a Member of Clinical Advisory Board at Receptos, Inc. He served as Member of Translational Advisory Board at Portola Pharmaceuticals, Inc. until September 25, 2015. He served a Director of Aventis Inc. (known as Rhone-Poulenc Rorer Inc.) since 1997. He served as a Member of Medical and Scientific Advisory Board at Forbes Medi Tech Inc. from January 7, 2004 to November 2004. He served as a Member of Scientific Advisory Board at DermTech, Inc. and Perlegen Sciences, Inc. He served as a Director of CardioPolymers, Inc. (also known as Symphony Medical, Inc.). He served as a Member of Medical Advisory Board at CardioNet, Inc. He served as Member of Advisory Board at Vascular Biogenics Ltd. (aka BioTelemetry, Inc.). He served as a Member of Advisory Board of Quintiles Transnational Corp. He serves as Fellow and Trustee of Society of Cardiac Angiography and Interventions. He was a Professor and Faculty at the University of Michigan. He has more than 1,000 original peer reviewed publications and has edited more than 30 books, including the Textbook of Interventional Cardiology (fifth edition), and the Textbook of Cardiovascular Medicine (third edition). Dr. Topol has been elected to the Institute of Medicine of the National Academy of Sciences, American Association of Physicians and American Society of Clinical Investigation. He has been recognized by Institute of Scientific Information to be in the top 10 of cited biomedical researchers in medicine from 1993 to 2003 and ranked first by Science Watch among authors of high impact papers in cardiovascular research from 1993 to 2000. In 2012, he published a book called The Creative Destruction of Medicine which examined the impact of both the genomic and wireless revolutions on the health care system. In 2013, he appeared on the Colbert Report and examined the host Stephen Colbert using several devices featured in his book. His most recent book The Patient Will See You Now (2015) explores how smart phones,

Mr. Jake B. Bauer has been the Principal Financial Officer at MyoKardia, Inc. since September 7, 2016 and serves as its Senior Vice President of Finance & Corporate Development since July 15, 2016. He serves as Assistant Secretary at MyoKardia, Inc. Mr. Bauer served as Vice President of Business Development and Business Operations at MyoKardia, Inc since July 2014 until July 15, 2016. Mr. Bauer served as Head of Corporate Development and Vice President of Business Operations at Ablexis, LLC. He served as Senior Director of Corporate Development and Business Operations at Ablexis, LLC. He was a Principal and Summer Associate at Third Rock Ventures, LLC. He joined Third Rock Ventures in 2007 as a Senior Associate. Mr. Bauer focused on opportunity analysis, new company formation, due diligence, deal sourcing and portfolio company support and management. In 2010, he helped open Third Rock 's office in San Francisco to support the West Coast-based portfolio companies and company creation efforts. He was actively involved in a variety of leading biopharmaceutical companies including Agios, CytomX, Global Blood Therapeutics and Zafgen. Mr. Bauer is involved in the formation of several portfolio companies and works with their management teams on operational and strategic issues through the first year post launch. Prior to this, Mr. Bauer was a Management Consultant at Putnam Associates, a Member of the investment team at RP Management, LLC (formerly Royalty Pharma), and a Member of the business development group at Endo International plc (formerly Endo Pharmaceuticals). He has significant experience in the biopharmaceutical industry and also has senior leadership experience, business development and business operations experience. He served as Board Observer at Ablexis, LLC. He served as a Director of Ablexis, LLC. He holds an M.B.A. from Harvard Business School. Mr. Bauer also holds a B.S. in Biology and a B.A. in Economics from Duke University.

Dr. Marc Semigran, M.D. serves as Medical Director of the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program and an Associate Professor at Medicine at Harvard Medical School. Dr. Semigran is an Advisor at Broadview Ventures, Inc. He serves as Chief Medical Officer at MyoKardia, Inc. since December 2016.His major research interest is in the role of right ventricular function in the pathophysiology of heart failure and in cardiac and vascular NO/cGMP signal transduction. He leads the NHLBI Heart Failure Network Regional Clinical Center at Harvard. Dr. Semigran also has a long standing interest in innovative approaches to amyloid heart disease including cardiac and stem-cell transplantation. Most recently, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director from 2004 to 2016. He is a recipient of NIH and industry research awards for this work. Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. Dr. Semigran is a graduate of the Harvard/MIT Health Sciences and Technology Program and completed Internal Medicine Residency and Cardiology Fellowship Training at Massachusetts General Hospital.

William Fairey serves as the Executive Vice President and Chief Commercial Officer of MyoKardia. William started at MyoKardia in January of 2019. William currently resides in the San Francisco Bay Area.

Lou Sehl serves as the Vice President, Manufacturing and Technical Operations of MyoKardia. Lou started at MyoKardia in July of 2018. Lou currently resides in the San Francisco Bay Area.

Johan Oslob serves as the Vice President, Chemistry of MyoKardia. Johan started at MyoKardia in January of 2018. Johan currently resides in the San Francisco Bay Area.

Lisa Alaimo serves as the VP, DCM program team leader of MyoKardia. Lisa started at MyoKardia in February of 2016. Lisa currently resides in the San Francisco Bay Area.

Jake Bauer serves as the Chief Business Officer of MyoKardia. Jake started at MyoKardia in April of 2018. Jake currently resides in the San Francisco Bay Area.